Lockheed Martin will host top performing Science, Technology, Engineering and Mathematics (STEM) high school students in two sessions today at its NexGen Cyber Innovation & Technology Center to promote cyber security careers and education, and to learn safe online practices through a series of interactive workshops.

By introducing Maryland high school students to cyber security at its Third Annual Cyber Security Awareness Day event, Lockheed Martin hopes to influence students to choose a career in cyber security and consider universities with a cyber security curriculum. This will help to fill the Bureau of Labor Statistics projected 65,700 new cyber security jobs between 2010 and 2020.


Join cybersecurity leaders, luminaries and rising stars at CyberMaryland 2012.

Be at the epicenter of information security and innovation during Cyber Security Awareness month when more than 1,000 people convene in Baltimore for the region’s premiere professional cybersecurity gathering.

Register today as a conference attendee, challenge participant, showcase exhibitor or awards banquet guest. CyberMaryland 2012 includes:

  • CyberMaryland Conference with 28+ Sessions in Three Tracks
  • Cyber Generation Showcase & Expo
  • Maryland Cyber Challenge & Competition (MDC3) for High School, College & Pro Teams
  • National Cyber Security Hall of Fame Inaugural Induction Ceremony & Awards Banquet


Thanks in part to its proximity to the federal government, the University of Maryland has shaped itself into one of the few institutions that specialize in cybersecurity — contributing its own resources, while also relying on financial contributions and expertise from the Washington area's biggest government contractors.

The university's latest announcement came Monday from Falls Church-based Northrop Grumman Corp. , which will provide UMd. a $1.1 million grant to create the nation's first cybersecurity honors program for undergraduates, dubbed the Advanced Cybersecurity Experience for Students. The program will kick off this fall, and Northrop will support it for an additional two years.


The incubator at University of Maryland, Baltimore County has gotten an influx of new tenants, the majority of whom are responding to the increased demand for cyber security. 

bwtech@UMBC Research and Technology Park currently hosts 86 incubator and early-stage tenants and 14 affiliated companies and organizations, according to Gregory Simmons, the park's vice president for institutional advancement.

Of the tenants, nearly 20 have joined the park in the past 18 months alone. They include Fearless Solutions, Rogue Technology, AIS (Assured Information Security) Inc., all of which are in the cyber security field.  Simmons says that most of the new tenants are also in that field, often in the area of securing data and networks, in medical, defense and financial services, among others.


Maryland and Montgomery County have signed a memorandum of understanding to create a National Cybersecurity Center of Excellence at the National Institute of Standards and Technology.

Lt. Gov. Anthony Brown, U.S. Sen. Barbara Mikulski and Montgomery County Executive Isiah Leggett took part in an event in Gaithersburg with Patrick Gallagher, director of the NIST on Tuesday.


Wednesday, September 7, 2016 - 6:00pm, CareFirst Tower, Baltimore, MD

We’re celebrating 11 years of raising awareness about sickle cell disease!  Put on something RED and join us at the CareFirst Tower in Canton for an evening of good food, fun and networking with friends – plus a glorious view of the Baltimore harbor.  We’re honoring Clinical Research Teams as Unsung Heroes.

Dr. Gary Gibbons, Director of NHLBI, will attend and receive a Distinguished Service Award.


RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a Method of Achieving a Thymosin Beta 4 Concentration in a Human Patient.  The patent covers treating a patient with a desired concentration of Thymosin Beta 4 (Tβ4) over a period of time, as well as treating a patient by maintaining a desired concentration of Tβ4 in a pharmacologically effective range.  The patent expiry will be in late 2031, or longer depending on any extensions available from the USPTO.


August 1, 2016: All Points, Maryland – Today Startup Maryland announced dates (September 10 – October 8) and the rough route for the STRT1UP Road Show, the fifth annual state-wide tour and celebration of entrepreneurship and high-growth innovation-centric startup companies.


Montgomery County Executive Ike Leggett is asking the business community to provide feedback on County services by completing an online Business Survey.

Mr. Leggett has kicked off the Excellence in Business Services initiative, continuing his efforts to make it easier for businesses to start, grow and thrive in Montgomery County. This business survey is designed to help the county identify areas of improvement in its interactions with business.

Business vitality is critical to a healthy economy that supports the quality of life we all enjoy and Montgomery County is committed to ensuring that businesses have a positive experience when interacting with the County.

Businesses also are welcome to contact the project lead directly with thoughts and feedback: Judy Stephenson This email address is being protected from spambots. You need JavaScript enabled to view it.


If immunotherapy has the cancer community riveted on the treatment side, liquid biopsies are equally exciting on the diagnostics end. And IBM is bringing its research heft to bear on the world of liquid biopsy with an intent to build a lab-on-a-chip technology that can separate particles at the nanoscale.


The Tech Council of Maryland is pleased to announce that Martin “Marty” Rosendale has been appointed as senior executive advisor.  In this role, he will assist the association and board of directors in fulfilling its strategic plan objectives.

Marty is a member of the Tech Council and is CEO of Selnova LLC, an advisory firm founded to help entrepreneurs navigate critical and challenging company transitions.  He is also a founding member of the managing committee that established and oversees TCM’s Venture Mentoring Service, where he and other TCM members act as mentors and provide their expertise to promising Maryland tech and life sciences companies that are preparing for an initial venture or institutional financing event.


Help MdBio Foundation kick off the school year with an ice cream cone and tour of MdBioLab.  Tour the lab, meet the team or just eat your ice cream.  Doors open 12 - 3PM.

 August 31, 2016  |  12PM - 3PM  |  JHU MoCo Parking Lot


EU and US strengthen their collaboration on eHealth IT

In December 2010, the US Department of Health and Human Services (HHS) and the European Commission's DG CONNECT signed a Memorandum of UnderstandingWeb Site Disclaimers (MoU) for transatlantic Cooperation on eHealth/Health IT.

In the spring of 2013, DG CONNECT and HHS published a first Roadmap of MoU actionsWeb Site Disclaimers, focusing on two priority areas (work-streams):


Submit your nominations for the Verl Zanders Emerging Business of the Year! Nominate your choice for an emerging company that is leading innovation in Metro-Maryland.

  • See the award criteria and past winners here.
  • Nominees do not have to be MCCC members.
  • Self-nominations are welcome.

Nomination Deadline: Friday, August 26, 2016


The Women In Bio (WIB) Washington DC/Baltimore Chapter and Association for Women in Science (AWIS) Bethesda Chapter invite you to a networking happy hour at La Tasca, Rockville, MD. Don’t miss the opportunity to meet and connect with industry professionals, entrepreneurs, and researchers, while enjoying sangrias and tapas at the lounge. This event is open to both members and non-members.

All guests will enjoy complimentary appetizers and two drink tickets


Maryland officials announced Tuesday that William Kirwan will chair the Maryland Commission on Innovation and Excellence in Education.   The panel will follow up on the work of the Thornton Commission, which resulted in 2002 legislation that set K-12 education aid formulas. Those have increased public school funding in Maryland by more than 100 percent over the past decade.


PathoVax was founded in late 2014 and is currently managed by myself (Weijie Poh, PhD) and Joshua Wang, PhD. We are both Singaporeans who were awarded fellowships to attend the Pathobiology graduate program at Johns Hopkins University, which is where the RGVax platform was developed. 

We also received training in Singapore under esteemed A*STAR investigators Dr Axel Ulrich (Weijie Poh) and Dr Lisa Ng (Joshua Wang). My research background included infectious diseases and cancer, and I have previously managed a biotech startup (Vector BioLabs) in Philadelphia where I oversaw business development, marketing and product expansion.


Digital Counties Survey award considered a top measures of government technology performance

For the fifth year in a row, Baltimore County is ranked among the top ten counties in the nation according to the Center for Digital Government’s 14th annual 2016 Digital Counties Survey in conjunction with the National Association of Counties (NACo).


Emergent BioSolutions Inc. (EBS) today announced that the Centers for Disease Control and Prevention (CDC) has exercised a contract option valued at $11.6 million over 12 months under contract 200-2012-52242 for the supply of Vaccinia Immune Globulin (VIGIV) into the U.S. Strategic National Stockpile. VIGIV is a therapeutic licensed by the U.S. Food and Drug Administration (FDA) for the treatment of complications due to smallpox vaccination. The contract option will require Emergent to conduct manufacturing runs and additional activities in support of maintaining FDA licensure of VIGIV.


Betamore personally invites BioHealth Innovation companies to apply to pitch and/or demo at Beta City 2016


BetaCity (9/29/2016) celebrates Baltimore’s place as a global destination for entrepreneurship

Seeking the Best + Brightest to Pitch + Demo

  • Pitch Competition: 3 PM - $75K+ to be awarded
  • Demo Companies showcase products/services to VIP’s, investors, and the broader community
  • Focus: Cybersecurity, Health IT, Other Technology

Other Notes

  • In addition to the Pitch Competition + Company Demos, the event will feature a VIP Reception, Awards Ceremony, Live Music + Merrymaking


Disruptors are a special type of innovator who go outside the box and attempt to change preconceived notions and practices. If you take a look at the meaning of the word, “to disrupt” means to “rupture” or break apart, and essentially disruptors do this - discarding the old ways to bring in new ones. We might even take it a step further and look at as the commonly used root of "dis" which means to "do the opposite of" - and see the idea that disruptors are "fixers" essentially putting the pieces of something broken back together. Here’s a look at three disruptors in Boston Biotech who are revolutionizing traditional pharma to radically change the ways cures are being brought about for disease.


Women of the Virginia bioscience community from across the state will lead this first-ever full day event offering examples of working together to build a stronger bioscience industry, stronger companies and institutions, stronger teams and networks, and stronger individuals.  

When: Thursday, September 29, 2016 10:00AM-5:00PM

Where: Inova Center for Personalized Health 3225 Gallows Rd Fairfax, Virginia  22037 United States


As members of a life sciences advisory and investment banking group, my partners and I have often noted that life sciences companies fall victim to the same mistakes and misconceptions, repeated again and again. These failures mostly hinge upon company management misunderstanding the fundamentals of market dynamics and failing to appreciate the importance of the exit—the sole event where company investors receive a return on their investment, either through an initial public offering (IPO) or a company sale. Unfortunately, the biotech industry's track record on exits is disappointing. According to the National Venture Capital Association (Washington, DC), between 2005 and 2014, only one in five US biotech and medical device companies achieved liquidity after six years. And from my perspective over the past 20 years, that low success rate does not appear to be improving.


Bristol-Myers Squibb’s acquisition of Cardioxyl Pharmaceuticals and its prodrug used to treat heart failure earned top honors in the Mergers and Acquisitions category from Thomson Reuters’ Allicense event on June 8.

Johns Hopkins Technology Ventures and a visiting researcher from the National Institutes of Health helped put the Johns Hopkins University scientists who compose the startup in touch, which led to the creation of Cardioxyl Pharmaceuticals.


In the past few years the wearables sector has been a hive of activity, but it feels like this year things have accelerated, particularly in the realm of health and wellness. A report by Forrester Research projected that 29 percent of Americans will use wearable devices, compared with 18 percent in 2015. It predicts that wearables sales will rise from $4.2 billion in 2015 to $9.8 billion in 2021.


QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced plans to return approximately $250 million to shareholders through a synthetic share repurchase proposal that combines a direct capital repayment with a reverse stock split.

These actions, which will lead to an adjustment in QIAGEN’s share capital, have been used previously by other large, multinational Dutch companies as an efficient way to provide returns to shareholders. The proposal, if adopted, is expected to be similar to QIAGEN repurchasing approximately $250 million of its own shares, but will enable the return of capital to all shareholders in a much faster and more efficient way than through a traditional open-market repurchase program.


Tioma Therapeutics, Inc., a venture-stage biopharmaceutical company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers, today announced it has raised $86 million in Series A venture financing. Proceeds from this financing will be used to further develop Tioma's antibody portfolio, including its lead drug candidate -- an anti-CD47 immune checkpoint inhibitor -- through advanced proof-of-concept in human clinical trials.


Companion diagnostics is gaining currency as novel drugs are being paired up with tests that determine which patients will have a higher chance of  responding to that drug.

But 15 years after the human genome project has been completed, the progress of precision medicine appears to be woefully slow, at least according to Nicholas Dracopoli, vice president and head of Oncology Biomarkers at Janssen Research & Development, part of Johnson & Johnson. Others believe precision medicine and companion diagnostics have a chicken and egg problem.


Defense IT firm Leidos today announced it has successfully closed on the acquisition of Bethesda, Maryland-based Lockheed Martin’s Information Systems & Global Solutions business, formalizing a deal announced in January.

With Lockheed Martin’s $5 billion IT business, Leidos becomes the government’s largest IT provider—nearly doubling its annual revenue to $10 billion—and further cements its place as a force in the growing federal health IT market.


The Maryland Life Sciences Advisory Board (LSAB) is developing recommendations to support the continued growth of the BioHealth industry in Maryland. The LSAB Working Group focused on Workforce and Access to Talent is seeking your input for their recommendations.

If you are involved with hiring/training employees, please take five minutes to complete this online survey by next Monday, August 22nd to have your feedback considered by the LSAB Workforce Working Group. (Please forward this survey to your HR manager/others if appropriate.)

Your input is valued. All responses will be kept confidential unless you ask for a member of the LSAB to contact you. If you have any questions or feedback for the other groups (Access to Capital, Technology Transfer, Foundational Support, Convergence of Bio and IT), please email the Maryland Department of Commerce at This email address is being protected from spambots. You need JavaScript enabled to view it..

Thank you for sharing your time and feedback.  


Symbiomix today announced it is accelerating plans for the commercial launch of Solosec™ (secnidazole) oral granules following the presentation of clinical results from the second pivotal trial for the treatment of bacterial vaginosis (BV) with the hiring of Taunia Markvicka, PharmD, MBA, as Chief Commercial Officer. Symbiomix had a significant presence at the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting in Annapolis, Maryland this past weekend with both the oral data presentation and sponsorship of a panel discussion on emerging diagnosis and treatment recommendations for BV. In addition, the company announced that the U.S. Food and Drug Administration (FDA) issued conditional acceptance of the proprietary name Solosec™. Solosec™ was previously known as SYM-1219.


In case you haven’t heard, BioBuzz just announced the launch of the BioHive – an Online Community and Collaboration Platform that is now open to general public. The BioHive will help enable all the components in our regional biotech ecosystem to work more efficiently to accelerate innovation, collaboration, workforce and growth opportunities.

Categorized into industry specific networks, the BioHive was built to bring together this region digitally and cultivate relationships that otherwise would not have been created due to company, role, geography, etc.

Please help us by pointing your coworkers and peers to the BioHive tab at or directly at to learn more and register for free today for their own BioHive account.

Working to build a stronger Biotech community has been BioBuzz’s mission for more than six years, so they are very excited to bring to you this great resource – so come join me on the BioHive!